Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03427476 · ClinicalTrials.gov registry record · Phase 1
CTT1057, a Small Molecular Inhibitor of PSMA, as a Novel Imaging Agent of Neovascularization in Renal Cell Carcinoma
A Phase 1 study, sponsored by Cancer Targeted Technology.
- Completed
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT03427476: Completed Phase 1 study, sponsored by Cancer Targeted Technology.
NCT03427476 is a Phase 1 study that has completed, run by Cancer Targeted Technology. The registered enrollment target is 4 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03427476, a Phase 1 study, has completed, sponsored by Cancer Targeted Technology.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
The purpose of this study is to test a novel diagnostic PET imaging agent for safety and biodistribution. The agent binds PSMA and is designed to detect Prostate Specific Membrane Antigen expressing tumors, such as has been described for some renal cell carcinoma tumors.
Interventions
- DRUG CTT1057
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2018-01-01 |
| Est. Completion | 2018-08-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03427476
The ClinicalTrials.gov registry entry for NCT03427476 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cancer Targeted Technology, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CTT1057 is the first listed.
NCT03427476 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03427476 about?
NCT03427476 is a clinical study titled "CTT1057, a Small Molecular Inhibitor of PSMA, as a Novel Imaging Agent of Neovascularization in Renal Cell Carcinoma". The purpose of this study is to test a novel diagnostic PET imaging agent for safety and biodistribution. The agent binds PSMA and is designed to detect Prostate Specific Membrane Antigen expressing tumors, such as has been described for some renal cell carcinoma tumors.
What is the current status of trial NCT03427476?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2018-01-01. Estimated completion is 2018-08-31.
What interventions are being tested in trial NCT03427476?
The interventions under investigation include: CTT1057 (DRUG).
Who is sponsoring clinical trial NCT03427476?
This trial is sponsored by Cancer Targeted Technology, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.